Selçuk Leyla Baykal, Akkuş Hande Ermiş, Akşan Burak, Arıca Deniz Aksu
Department of Dermatology and Venereology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
Ankara Sincan Training and Research Hospital, Ankara, Turkey.
An Bras Dermatol. 2025 Mar-Apr;100(2):293-299. doi: 10.1016/j.abd.2024.05.005. Epub 2025 Jan 9.
Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies.
In this study, the authors evaluated the effectiveness and safety of two of these over a 52-week treatment period.
A double-center retrospective cohort study was conducted, enrolling patients with moderate to severe psoriasis who received either guselkumab or risankizumab at dermatology clinics for a minimum of 52-weeks.
Out of the 90 patients enrolled in the study, 49 (54.4%) received guselkumab, while 41 (45.6%) received risankizumab. Regarding therapy efficiency, there was no statistically significant difference in PASI90 and PASI100 at week 4 between the two groups (p = 0.428, p = 0.750, respectively). By week 16, PASI90 responses were higher in the guselkumab group (p = 0.039). However, there was no difference in PASI100 response at week 16 (p = 0.957). At weeks 24 and 52, PASI90 and PASI100 responses were similar in both groups. Our results demonstrated that both guselkumab and risankizumab were effective in patients who had previously failed other biologics. Clinical outcomes in both the guselkumab and risankizumab groups had remained unaffected during prior biologic treatments, including anti-TNF, anti-IL17, and/or anti-IL12/23. Treatments yielded consistent outcomes regardless of factors such as obesity, gender, and comorbidities.
The small sample size.
Our results demonstrated that both guselkumab and risankizumab were effective in patients who had previously failed other biologics. Clinical outcomes in both the guselkumab and risankizumab groups had remained unaffected during prior biologic treatments, including anti-TNF, anti-IL17, and/or anti-IL12/23. Treatments yielded consistent outcomes regardless of factors such as obesity, gender, and comorbidities.
银屑病是一种具有遗传易感性和自身免疫成分的慢性炎症性皮肤病，常采用生物疗法等免疫调节剂进行治疗。
在本研究中，作者评估了其中两种药物在52周治疗期内的有效性和安全性。
进行了一项双中心回顾性队列研究，纳入中度至重度银屑病患者，这些患者在皮肤科诊所接受古塞库单抗或司库奇尤单抗治疗至少52周。
在该研究纳入的90例患者中，49例（54.4%）接受了古塞库单抗治疗，而41例（45.6%）接受了司库奇尤单抗治疗。关于治疗效果，两组在第4周时的PASI90和PASI100方面无统计学显著差异（分别为p = 0.428，p = 0.750）。到第16周时，古塞库单抗组的PASI90反应更高（p = 0.039）。然而，在第16周时PASI100反应无差异（p = 0.957）。在第24周和第52周时，两组的PASI90和PASI100反应相似。我们的结果表明，古塞库单抗和司库奇尤单抗对先前其他生物制剂治疗失败的患者均有效。在先前包括抗TNF、抗IL17和/或抗IL12/23的生物制剂治疗期间，古塞库单抗组和司库奇尤单抗组的临床结局均未受影响。无论肥胖、性别和合并症等因素如何，治疗均产生一致的结果。
样本量小。
我们的结果表明，古塞库单抗和司库奇尤单抗对先前其他生物制剂治疗失败的患者均有效。在先前包括抗TNF、抗IL17和/或抗IL12/23的生物制剂治疗期间，古塞库单抗组和司库奇尤单抗组的临床结局均未受影响。无论肥胖、性别和合并症等因素如何，治疗均产生一致的结果。
